DR. HOWARD J. WORMAN, M.D.
Osteopathic Medicine at Fort Washington Ave, New York, NY

7094401, Aug 22, 2006

Sep 29, 1999

09/407432

Howard J. Worman - New York NY, US
Naoto Mamiya - Aichi, JP

The Trustees of Columbia University in the City of New York - New York NY

A61K 38/43

424 941, 42419611, 435 5, 435 71, 435183, 435188, 435 15, 435193

The present invention provides a method of treating or preventing hepatitis C virus infection in a subject which comprises administering an effective amount of an agent to the subject, wherein the agent is capable of specifically binding to the HCV core protein so as to inhibit hepatitis C virus replication. The present invention also provides a method for determining whether a compound can treat or prevent hepatitis C virus infection in a subject, wherein the compound treats or prevents hepatitis C virus infection by specifically inhibiting the binding of HCV core protein and said agent so as to suppress hepatitis C virus replication. The present invention further provides a composition for inhibiting cell growth, comprises a HCV core protein or a variant thereof, wherein said HCV core protein or its variant inhibit cancer cell growth by inhibiting the cellular DEAD box proteins.

2002016, Oct 31, 2002

Sep 29, 1999

09/407430

HOWARD J. WORMAN - NEW YORK NY, US
NAOTO MAMIYA - CHITA-GUN, JP

A01N037/18, C07H021/04, C07K001/00, C07K014/00, C07K017/00, A61K038/00

514/002000, 530/350000, 536/023500

The present invention provides a method of treating or preventing hepatitis C virus infection in a subject which comprises administering an effective amount of an agent to the subject, wherein the agent is capable of inhibiting the attachment of hepatitis C virus onto cells by specifically binding to the hepatitis C virus envelope E2 protein so as to treat or prevent hepatitis C virus infection. The present invention also provides a method of identifying a compound which can inhibit the attachment of hepatitis C virus onto cells and can treat or prevent hepatitis C virus infection in a subject by inhibiting the binding of hepatitis C virus envelope E2 protein to a cellular protein associated with hepatitis C virus attachment onto cells and their entry into cells, comprising (a) incubating said compound, the hepatitis C virus envelope E2 protein or its variant and said cellular protein capable of specifically binding to said hepatitis C virus E2 protein under a suitable reaction conditions, (b) determining the interactions between the hepatitis C virus envelope E2 protein or its variant and said cellular protein in the presence of said compound, and (c) comparing the interactions in step (b) with the interaction between the hepatitis C virus envelope E2 protein or its variant and said cellular protein in the absence of said compound so as to identify a compound which can inhibit the attachment of hepatitis C virus into a cell.

2003000, Jan 2, 2003

Jun 15, 2001

09/882325

Howard Worman - New York NY, US
Birgit Terjung - Swisttal, DE

G01N033/567, C07K014/435

435/007210, 530/350000

The present invention is directed to the molecular characterization of the nuclear antigen recognized by atypical p-antineutrophil cytoplasmic antibodies (p-ANCA) in order to better diagnose patients with inflammatory bowel diseases such as ulcerative colitis (UC), and autoimmune liver diseases such as primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH). Molecular characterization of the target antigen comprises preparing cytoplasmic and nuclear extracts of human neutrophils, human HL-60 and murine 32D myeloid cells. Proteins should then be resolved by 1 and 2 dimensional gel electrophoresis and reactive proteins can then be detected by immunoblotting with sera from individuals, making certain to have both normal and disease controls. Atypical p-ANCA should then be affinity purified against the reactive protein and investigated for their immunofluorescence pattern using confocal microscopy. One could then detect the antigen that atypical p-ANCA can recognize and use that antigen to detect the prescence of atypical p-antineutrophil cytoplasmic antibodies so as to diagnose patients with inflammatory bowel diseases such as ulcerative colitis (UC), and autoimmune liver diseases such as sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH).

2011011, May 12, 2011

Nov 1, 2010

12/917136

Howard J. Worman - New York NY, US
Antoine Muchir - New York NY, US

A61K 38/45, A61K 31/166, A61K 31/4184, A61K 31/352, A61K 31/277, A61K 31/416, A61K 31/454, A61P 9/00

424 945, 514575, 514394, 514456, 514523, 514406, 514326

Provided is a method of treating or preventing a cardiomyopathy associated with activation of at least one kinase in the MAP kinase signaling pathway in heart tissue by providing to a subject an inhibitor of at least one kinase in the ERK signaling pathway or in the JNK signaling pathway, or both. In some embodiments, the cardiomyopathy is associated with one or more mutations in the LMNA gene, which encodes A-type nuclear lamins, or in the EMD gene, which encodes an inner nuclear membrane protein.